JMP Securities Maintains Market Outperform on Intellia Therapeutics, Raises Price Target to $111

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and raises the price target from $106 to $111.

Total
0
Shares
Related Posts
Read More

Expert Ratings for Expedia Group

Over the past 3 months, 14 analysts have published their opinion on Expedia Group (NASDAQ:EXPE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

EXPE